Skin News and Research

RSS

U.S. Marshals seizes unapproved drug products

At the request of the U.S. Food and Drug Administration, U.S. Marshals on March 31 seized a range of consumer products, including creams, capsules, tablets, gum, throat spray, and shampoos from a Haywood, Wis., manufacturer.

6 Apr 2010

Qutenza 8% patch now available for pain associated with PHN: NeurogesX

NeurogesX, Inc. announced today that Qutenza® (capsaicin) 8% patch, the first and only product containing prescription-strength capsaicin, is now available. Clinical studies have shown that a single one-hour Qutenza application can provide three months relief from pain associated with postherpetic neuralgia, the nerve pain that can occur after shingles.

6 Apr 2010

Plexiglas robot sees in the dark much like blind cave fish Astyanax

Clever as a blind fish, the underwater robot "Snookie" can orient itself in murky waters with an artificial sensory organ inspired by the so-called lateral-line system, found in fish and some amphibians. The experimental vehicle was developed by researchers at the Technische Universitaet Muenchen within the framework of the CoTeSys (Cognition for Technical Systems) excellence cluster. In the future, the researchers expect such capabilities to enable underwater robots to work autonomously in operations ranging from deep sea exploration to inspection of sewer pipes.

5 Apr 2010

Is relief round the corner for multiple sclerosis patients in the form of bee stings?

A recent development can raise the hopes of many sufferers of Multiple Sclerosis (MS) – a dreaded, debilitating, fatal nerve disorder. Charity worker Sami Chugg, 45, claims to have overcome her condition after being stung by bees.

5 Apr 2010

Study: Trial vaccine eliminates residual cancer cells in CML patients

Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).

3 Apr 2010

Cancer Prevention Coalition's statement on new nominated NCI Director

Last Wednesday, the White House nominated Nobel Laureate Harold Varmus as Director of the National Cancer Institute.

3 Apr 2010

Scientific American features Echo Therapeutics' non-invasive, wireless Symphony tCGM System

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, announced today that its Symphony™ tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings," by Larry Greenemeier.

3 Apr 2010

NAFC supports PMAA of Uromedica's ACT device for SUI, speaks to FDA

On March 24, Nancy Muller, executive director of The National Association For Continence (NAFC), spoke to the Food and Drug Administration (FDA), in support of a Premarket Approval Application (PMAA) of Uromedica, Inc.'s Adjustable Continence Therapy (ACT®) device to approve its usage in the U.S. The ACT is designed to treat female stress urinary incontinence (SUI).

2 Apr 2010

Sunshine vitamin cures common health problems

What do obesity, heart disease, depression, diabetes, and fibromyalgia have in common? The answer is vitamin D deficiency. More than 200 million Americans lack this essential vitamin and as a result suffer from a host of daily annoyances, chronic conditions, and even life-threatening illnesses.

2 Apr 2010

Protein vaccines for needle-free immunization through the skin

Most immunizations currently involve an injection in the arm. In the future, vaccination may be accomplished without the unpleasant jab of a needle: a team led by Victor C. Yang at the University of Michigan (USA) has developed a method by which vaccines can pass directly through the skin without a needle. As the researchers report in the journal Angewandte Chemie, merely linking a special short peptide molecule to the vaccine, which can then be administered in the form of a patch, will do the job.

1 Apr 2010

Canadians can join Canadian Cancer Society in the fight against cancer

With the support of generous corporate partners, the Canadian Cancer Society is fighting back against cancer. This April, the Society will raise funds and awareness in partnership with companies across Canada. Supporting the companies that support the Canadian Cancer Society is another way Canadians can join the fight against cancer.

1 Apr 2010

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.

1 Apr 2010

Role of membrane cholesterol in late keratinocyte differentiation analyzed

In a recent study initiated by Beiersdorf AG, Florian Spörl and colleagues evaluated the use of Roche Applied Science's xCELLigence System as a viable system to monitor not only cholesterol extraction and repletion but also cholesterol reorganization in human keratinocytes in real time. The xCELLigence System offers a novel approach to non-invasive long-term observation of membrane cholesterol dynamics in primary human keratinocytes.

1 Apr 2010

Cell study may yield new treatment strategies for debilitating diseases

A Los Alamos National Laboratory toxicologist and a multidisciplinary team of researchers have documented potential cellular damage from "fullerenes"-soccer-ball-shaped, cage-like molecules composed of 60 carbon atoms. The team also noted that this particular type of damage might hold hope for treatment of Parkinson's disease, Alzheimer's disease, or even cancer.

1 Apr 2010

People in 60s and 70s more likely to be diagnosed with skin cancer

People in their 60s and 70s are now over five times more likely to be diagnosed with malignant melanoma - the deadliest type of skin cancer - than their parents would have been 30 years ago, reveal new Cancer Research UK statistics1 to launch the 2010 SunSmart campaign today (Thursday).

1 Apr 2010

Hemosphere completes $9.3M venture capital financing

Hemosphere, Inc., a private medical device company, has completed a late round of venture capital financing totaling $9.3 million. The company has developed the HeRO® Vascular Access Device, which provides access for hemodialysis - the process of filtering waste products from blood when kidneys are in renal failure - similar to a conventional graft.

1 Apr 2010

SANUWAVE Health reports net loss of $2.7M for three months ended December 31, 2009

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, reports its financial results for the fourth quarter and full year ended December 31, 2009, and on its progress for the year.

31 Mar 2010

Cryo-Cell International, MOSI partner to develop educational exhibit on stem cells and regenerative science

Cryo-Cell International Inc., a global leader of innovative stem cell solutions and stem cell cryopreservation services, today announced plans to partner with Museum of Science & Industry (MOSI) in the development and launch of an interactive educational exhibit on stem cells and regenerative science. Cryo-Cell is one of the most established private family cord blood banks and is a pioneer in the stem cell industry.

31 Mar 2010

$Notch pathway could aid treatment of osteoporosis, fractures and arthritis$

Notch pathway could aid treatment of osteoporosis, fractures and arthritis

Scientists seeking new ways to fight maladies ranging from arthritis and osteoporosis to broken bones that won't heal have cleared a formidable hurdle, pinpointing and controlling a key molecular player to keep stem cells in a sort of extended infancy.

31 Mar 2010

PolyMedix completes Phase 1B clinical study with PMX-30063 defensin-mimetic antibiotic

PolyMedix, Inc., an emerging bio-technology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B clinical study with its novel defensin-mimetic antibiotic, PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.

31 Mar 2010